VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. This strategic move comes as the company seeks to strengthen its financial leadership to support its capital strategy and the continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener brings more than three decades of international financial leadership experience, spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. His extensive background is expected to be instrumental as VERAXA advances its clinical programs and explores strategic opportunities. He will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and will play a key role in shaping the company's financial future.
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025. During his tenure, he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
The appointment of a seasoned financial executive like Willener is particularly significant for VERAXA, which is in the highly competitive field of oncology drug development. The company's proprietary BiTAC(R) platform, which is based on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), represents a novel approach to cancer therapy. With Willener's experience in capital markets and asset management, VERAXA is well-positioned to secure the necessary funding to advance its pipeline and potentially bring innovative treatments to patients.
The company's focus on next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs, places it at the forefront of a rapidly evolving sector. As the demand for more effective cancer treatments grows, VERAXA's ability to attract top-tier financial leadership underscores its commitment to innovation and growth.
Willener's appointment comes at a time when the biotech industry is facing increasing pressure to deliver results. His proven track record in financial strategy and corporate development will be vital as VERAXA navigates the complexities of clinical development, regulatory approvals, and potential commercialization.
For more information on VERAXA Biotech and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA. To view the full press release, see https://nnw.fm/jcHOU.
